Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment

To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA,...

Full description

Bibliographic Details
Authors: Vela, Paloma|||0000-0001-8566-5172, Sanchez-Piedra, Carlos, Pérez-García, Carolina|||0000-0002-6695-6406, Castro-Villegas, Ma Carmen, Freire, Mercedes, Mateo, Lourdes|||0000-0002-6394-2949, Diaz-Torne, Cesar|||0000-0001-6275-7699, Bohórquez, Cristina, Blanco-Madrigal, Juan M., Ros-Vilamajo, Inmaculada, Gómez, Silvia, Caño, Rocio, Sánchez-Alonso, Fernando, Díaz-González, Federico|||0000-0002-4139-9295, Gómez-Reino, Juan J.
Format: article
Publication Date:2020
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:284609
Online Access:https://ddd.uab.cat/record/284609
https://dx.doi.org/urn:doi:10.1186/s13075-020-02231-x
Access Level:Open access
Keyword:Ankylosing spondylitis
Biologics
Elderly-onset rheumatoid arthritis
Psoriatic arthritis
Rheumatoid arthritis
Description
Summary:To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA, and classified as young (< 25 years old), adult (25-64 years old), elderly (65-75 years old) or very elderly (.

Similar Items